Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kazumi Sano

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan|November 2, 2004
Beta-adrenergic blocking agents and intermittent claudication: systematic reviewRitsuko Miyajima, Kazumi Sano, Hisahiro Yoshida
BMC Cancer|April 8, 2020
Minocycline prevents and repairs the skin disorder associated with afatinib, one of the epidermal growth factor receptor-tyrosine kinase inhibitors for non-small cell lung cancerKazumi Sano, Kazuhiko Nakadate, Kazuhiko Hanada
The Journal of Pharmacy and Pharmacology|February 19, 2002
Metabolism of sulphobromophthalein II. Species differences between rats, guinea-pigs and rabbitsKazumi Sano, Yukari Totsuka, Yoji Ikegami, et al.
Current Pharmaceutical Design|February 4, 2006
Transport mechanism-based drug molecular design: novel camptothecin analogues to circumvent ABCG2-associated drug resistance of human tumor cellsToshihisa Ishikawa, Yoji Ikegami, Kazumi Sano, et al.
Internal Medicine (Tokyo, Japan)|July 10, 2018
Pharmacokinetics of Isoniazid-induced Rhabdomyolysis in a GirlKoyuru Kurane, Masahide Goto, Kazumi Sano, et al.
Kekkaku : [Tuberculosis]|December 18, 2013
[Drunkenness caused by isoniazid in a tuberculosis patient with extrapulmonary lesions on hemodialysis: a case report]Masafumi Saiki, Takayuki Honda, Yusuke Sogami, et al.
Clinical and Translational Science|April 22, 2020
Phase I/II Study of Erlotinib to Determine the Optimal Dose in Patients With Non-Small Cell Lung Cancer Harboring Only EGFR MutationsYuichiro Takeda, Naoki Ishizuka, Kazumi Sano, et al.
Journal of Experimental Therapeutics & Oncology|July 17, 2004
Transport of SN-38 by the wild type of human ABC transporter ABCG2 and its inhibition by quercetin, a natural flavonoidMegumi Yoshikawa, Yoji Ikegami, Kazumi Sano, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 22, 2005
Genomic evolution of MHC class I region in primatesKaoru Fukami-Kobayashi, Takashi Shiina, Tatsuya Anzai, et al.
Chemotherapy|January 25, 2014
Gefitinib enhances the antitumor activity of CPT-11 in vitro and in vivo by inhibiting ABCG2 but not ABCB1: a new clue to circumvent gastrointestinal toxicity riskYutaka Inoue, Yoji Ikegami, Kazumi Sano, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan|November 2, 2004
Beta-adrenergic blocking agents and intermittent claudication: systematic reviewRitsuko Miyajima, Kazumi Sano, Hisahiro Yoshida
BMC Cancer|April 8, 2020
Minocycline prevents and repairs the skin disorder associated with afatinib, one of the epidermal growth factor receptor-tyrosine kinase inhibitors for non-small cell lung cancerKazumi Sano, Kazuhiko Nakadate, Kazuhiko Hanada
The Journal of Pharmacy and Pharmacology|February 19, 2002
Metabolism of sulphobromophthalein II. Species differences between rats, guinea-pigs and rabbitsKazumi Sano, Yukari Totsuka, Yoji Ikegami, et al.
Current Pharmaceutical Design|February 4, 2006
Transport mechanism-based drug molecular design: novel camptothecin analogues to circumvent ABCG2-associated drug resistance of human tumor cellsToshihisa Ishikawa, Yoji Ikegami, Kazumi Sano, et al.
Internal Medicine (Tokyo, Japan)|July 10, 2018
Pharmacokinetics of Isoniazid-induced Rhabdomyolysis in a GirlKoyuru Kurane, Masahide Goto, Kazumi Sano, et al.
Kekkaku : [Tuberculosis]|December 18, 2013
[Drunkenness caused by isoniazid in a tuberculosis patient with extrapulmonary lesions on hemodialysis: a case report]Masafumi Saiki, Takayuki Honda, Yusuke Sogami, et al.
Clinical and Translational Science|April 22, 2020
Phase I/II Study of Erlotinib to Determine the Optimal Dose in Patients With Non-Small Cell Lung Cancer Harboring Only EGFR MutationsYuichiro Takeda, Naoki Ishizuka, Kazumi Sano, et al.
Journal of Experimental Therapeutics & Oncology|July 17, 2004
Transport of SN-38 by the wild type of human ABC transporter ABCG2 and its inhibition by quercetin, a natural flavonoidMegumi Yoshikawa, Yoji Ikegami, Kazumi Sano, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 22, 2005
Genomic evolution of MHC class I region in primatesKaoru Fukami-Kobayashi, Takashi Shiina, Tatsuya Anzai, et al.
Chemotherapy|January 25, 2014
Gefitinib enhances the antitumor activity of CPT-11 in vitro and in vivo by inhibiting ABCG2 but not ABCB1: a new clue to circumvent gastrointestinal toxicity riskYutaka Inoue, Yoji Ikegami, Kazumi Sano, et al.
Pageof 3